Timing of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Patients With Lung Cancer With EGFR MutationsMORAN, Teresa; SEQUIST, Lecia V.Journal of clinical oncology. 2012, Vol 30, Num 27, pp 3330-3336, issn 0732-183X, 7 p.Article

Complex Role of Histone Deacetylase Inhibitors in the Treatment of Non―Small-Cell Lung CancerNEAL, Joel W; SEQUIST, Lecia V.Journal of clinical oncology. 2012, Vol 30, Num 18, pp 2280-2282, issn 0732-183X, 3 p.Article

A 55-Year-Old Man with Oligometastatic Lung CancerLANUTI, Michael; SEQUIST, Lecia V; SHARMA, Amita et al.The New England journal of medicine. 2011, Vol 365, Num 15, pp 1426-1435, issn 0028-4793, 10 p.Article

A Man with Back Pain and a Mass in the LungSEQUIST, Lecia V; SETTLEMAN, Jeffrey E; ACKMAN, Jeanne B et al.The New England journal of medicine. 2008, Vol 359, Num 4, pp 405-414, issn 0028-4793, 10 p.Article

Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancerSEQUIST, Lecia V; BELL, Daphne W; LYNCH, Thomas J et al.Journal of clinical oncology. 2007, Vol 25, Num 5, pp 587-595, issn 0732-183X, 9 p.Article

EGFR-Activating Mutations Correlate with a Fanconi Anemia―like Cellular Phenotype That Includes PARP Inhibitor SensitivityPFÄFFLE, Heike N; MENG WANG; WILLERS, Henning et al.Cancer research (Chicago, Ill.). 2013, Vol 73, Num 20, pp 6254-6263, issn 0008-5472, 10 p.Article

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR MutationsSEQUIST, Lecia V; YANG, James Chih-Hsin; SU, Wu-Chou et al.Journal of clinical oncology. 2013, Vol 31, Num 27, pp 3327-3334, issn 0732-183X, 8 p.Article

RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasisMIN YU; TIN, David T; ULMAN, Matthew J et al.Nature (London). 2012, Vol 487, Num 7408, pp 510-513, issn 0028-0836, 4 p.Article

Detection of Mutations in EGFR in Circulating Lung-Cancer CellsMAHESWARAN, Shyamala; SEQUIST, Lecia V; DIGUMARTHY, Subba et al.The New England journal of medicine. 2008, Vol 359, Num 4, pp 366-377, issn 0028-4793, 12 p.Article

Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomasTARON, Miguel; ICHINOSE, Yukito; JAHAN, Thierry et al.Clinical cancer research. 2005, Vol 11, Num 16, pp 5878-5885, issn 1078-0432, 8 p.Article

Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted DrugsKRIS, Mark G; JOHNSON, Bruce E; YU SHYR et al.JAMA, the journal of the American Medical Association. 2014, Vol 311, Num 19, pp 1998-2006, issn 0098-7484, 9 p.Article

Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non-Small-Cell Lung CancerSEQUIST, Lecia V; GETTINGER, Scott; SWEENEY, Jennifer et al.Journal of clinical oncology. 2010, Vol 28, Num 33, pp 4953-4960, issn 0732-183X, 8 p.Article

Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non-Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical TrialsJACKMAN, David M; MILLER, Vincent A; CIOFFREDI, Leigh-Anne et al.Clinical cancer research (Print). 2009, Vol 15, Num 16, pp 5267-5273, issn 1078-0432, 7 p.Article

Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemiaGRIBBEN, John G; ZAHRIEH, David; SOIFFER, Robert J et al.Blood. 2005, Vol 106, Num 13, pp 4389-4396, issn 0006-4971, 8 p.Article

Characteristics of Lung Cancers Harboring NRAS MutationsOHASHI, Kadoaki; SEQUIST, Lecia V; YUMEI PAN et al.Clinical cancer research (Print). 2013, Vol 19, Num 9, pp 2584-2591, issn 1078-0432, 8 p.Article

Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With EGFR MutationsYANG, James Chih-Hsin; HIRSH, Vera; PALMER, Michael et al.Journal of clinical oncology. 2013, Vol 31, Num 27, pp 3342-3350, issn 0732-183X, 9 p.Article

Anaplastic Lymphoma Kinase Inhibition in Non-Small-Cell Lung CancerKWAK, Eunice L; BANG, Yung-Jue; VARELLA-GARCIA, Marileila et al.The New England journal of medicine. 2010, Vol 363, Num 18, pp 1693-1703, issn 0028-4793, 11 p.Article

Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to GefitinibCOSTA, Daniel B; NGUYEN, Kim-Son H; HUBERMAN, Mark S et al.Clinical cancer research (Print). 2008, Vol 14, Num 21, pp 7060-7067, issn 1078-0432, 8 p.Article

Isolation of rare circulating tumour cells in cancer patients by microchip technologyNAGRATH, Sunitha; SEQUIST, Lecia V; RYAN, Paula et al.Nature (London). 2007, Vol 450, Num 7173, pp 1235-1239, issn 0028-0836, 5 p.Article

Novel agents in the treatment of lung cancer : Fourth cambridge conferenceLYNCH, Thomas J; BONOMI, Philip D; PEREZ-SOLER, Roman et al.Clinical cancer research. 2007, Vol 13, Num 15, issn 1078-0432, 4583s-4586s, 2Conference Paper

A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non―Small Cell Lung CancerSOCINSKI, Mark A; GOLDMAN, Jonathan; BONOMI, Philip et al.Clinical cancer research (Print). 2013, Vol 19, Num 11, pp 3068-3077, issn 1078-0432, 10 p.Article

Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non-Small-Cell Lung CancerSEQUIST, Lecia V; VON PAWEL, Joachim; RAMLAU, Rodryg et al.Journal of clinical oncology. 2011, Vol 29, Num 24, pp 3307-3315, issn 0732-183X, 9 p.Article

Neratinib, an Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor: Results of a Phase II Trial in Patients With Advanced Non―Small-Cell Lung CancerSEQUIST, Lecia V; BESSE, Benjamin; ANANTHAKRISHNAN, Revathi et al.Journal of clinical oncology. 2010, Vol 28, Num 18, pp 3076-3083, issn 0732-183X, 8 p.Article

First-Line Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring Somatic EGFR MutationsSEQUIST, Lecia V; MARTINS, Renato G; KUHLMANN, Georgiana L et al.Journal of clinical oncology. 2008, Vol 26, Num 15, pp 2442-2448, issn 0732-183X, 7 p.Article

Reduced Erlotinib Sensitivity of Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer following Cisplatin Exposure : A Cell Culture Model of Second-line Erlotinib TreatmentTAN MIN CHIN; QUINLAN, Margaret P; SINGH, Anurag et al.Clinical cancer research (Print). 2008, Vol 14, Num 21, pp 6867-6876, issn 1078-0432, 10 p.Article